Shares of Editas Medicine Inc (NASDAQ:EDIT) have earned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $41.67.

Several equities research analysts have issued reports on the company. Zacks Investment Research downgraded Editas Medicine from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. BidaskClub raised Editas Medicine from a “hold” rating to a “buy” rating in a report on Tuesday, December 4th. ValuEngine downgraded Editas Medicine from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Cowen reaffirmed a “buy” rating on shares of Editas Medicine in a report on Tuesday, January 22nd. Finally, Chardan Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Editas Medicine in a report on Tuesday, January 22nd.

In other Editas Medicine news, CEO Katrine Bosley sold 12,000 shares of the firm’s stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $25.27, for a total transaction of $303,240.00. Following the completion of the sale, the chief executive officer now owns 1,204,966 shares of the company’s stock, valued at approximately $30,449,490.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew A. F. Hack sold 7,000 shares of the firm’s stock in a transaction on Friday, January 4th. The shares were sold at an average price of $22.48, for a total value of $157,360.00. Following the sale, the chief financial officer now directly owns 7,000 shares of the company’s stock, valued at approximately $157,360. The disclosure for this sale can be found here. Insiders have sold a total of 38,895 shares of company stock valued at $927,364 in the last ninety days. Insiders own 5.20% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. We Are One Seven LLC acquired a new stake in shares of Editas Medicine during the fourth quarter worth $40,000. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Editas Medicine by 48.7% during the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 3,055 shares of the company’s stock worth $70,000 after buying an additional 1,000 shares in the last quarter. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Editas Medicine during the fourth quarter worth $109,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of Editas Medicine by 34.2% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,160 shares of the company’s stock worth $113,000 after buying an additional 1,314 shares in the last quarter. Finally, Ancora Advisors LLC acquired a new stake in shares of Editas Medicine during the third quarter worth $127,000. 70.19% of the stock is owned by institutional investors.

NASDAQ:EDIT opened at $23.63 on Friday. Editas Medicine has a 1-year low of $17.80 and a 1-year high of $41.43. The company has a debt-to-equity ratio of 0.14, a current ratio of 10.44 and a quick ratio of 10.44. The firm has a market capitalization of $1.16 billion, a P/E ratio of -10.14 and a beta of 2.50.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Thursday, February 28th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). Editas Medicine had a negative net margin of 344.28% and a negative return on equity of 46.82%. The business had revenue of $6.12 million for the quarter, compared to analyst estimates of $16.30 million. As a group, sell-side analysts anticipate that Editas Medicine will post -2.74 EPS for the current year.

Editas Medicine Company Profile

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Featured Story: How to calculate the annual rate of depreciation

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.